Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Amgen (NASDAQ: AMGN) executive commentary continued through the weekend of September 12-13, 2026 following Thursday's Wells Fargo Healthcare Conference in Boston, reinforcing that MariTide (maridebart cafraglutide, antibody-peptide conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody scaffold) is Amgen's sole obesity asset following the August 4, 2026 Q2 earnings-call disclosure that Amgen had discontinued Phase 1 candidate AMG 513. The AMG 513 discontinuation followed a similar Amgen fate for AMG 786 in 2024 and reflects the company's high internal efficacy bar for obesity assets against the emerging retatrutide (Lilly, ~28% weight loss in TRIUMPH-1) and CagriSema (Novo, ~20% in REDEFINE) benchmarks. Amgen's positioning for MariTide anchors on 8-week or quarterly maintenance dosing (4-6 doses per year), Phase 2 20% weight loss at 52 weeks, and cardiometabolic secondary benefits (triglycerides, hs-CRP, blood pressure). MARITIME-SWITCH Phase 3 tests conversion from weekly injectable semaglutide or tirzepatide to monthly MariTide. Analysts continue to seek Amgen M&A activity to broaden the obesity asset base, but company executives at Wells Fargo said the late-stage pipeline is largely full and business development will focus on earlier-stage opportunities.
Roivant Sciences (NASDAQ: ROIV) analyst commentary continued through the weekend following Tuesday's Pulmovant Phase 2 PHocus mosliciguat win, with Leerink Partners' David Risinger flagging up to $10 billion peak sales potential for mosliciguat across multiple pulmonary hypertension indications. The Leerink estimate substantially exceeds the ~$3 billion PH-ILD-only estimate Guggenheim disclosed Wednesday September 9. Other analyst peak sales projections ranged from $1.5 billion to $5 billion depending on indication assumptions and market-share methodology. The week's analyst upgrade sequence: Jefferies to $52 (from $42), Guggenheim to $46 (from $42), Piper Sandler to $55 (from $40), TD Cowen to $55 (from $50), BofA also raised. Consensus 12-month price target clusters around $50-55. The PHocus trial produced a 56.3% placebo-adjusted PVR reduction at Week 16 (p<0.0001), 6MWD +35.2 meters, and NT-proBNP −357.7 pg/mL (−53.2%). The Phase 3 PHrontier trial in approximately 375 patients is enrolling. Mosliciguat's mechanism (inhaled soluble guanylate cyclase activator working independently of heme and nitric oxide) differentiates it from sGC stimulators like Bayer's Adempas (riociguat) and prostacyclin analogs like United Therapeutics' Tyvaso (treprostinil).
Ionis Pharmaceuticals (NASDAQ: IONS) CEO Brett Monia participated in a fireside chat Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, disclosing TRYNGALZA (olezarsen, an antisense oligonucleotide that reduces apolipoprotein C-III production and lowers triglycerides) H1 2026 U.S. net product sales of $32 million (Q2 alone was $5 million) with full-year 2026 guidance of $100-110 million. The severe hypertriglyceridemia (sHTG) launch followed June 2026 FDA approval and represents the first indication expansion from the initial familial chylomicronemia syndrome (FCS) indication. Ionis raised peak sales guidance in the sHTG indication from $1 billion-plus to $2 billion-plus. The sHTG marketing application is under review in the European Union with potential launch in 2027. Ionis is also commercializing the September 3, 2026 FDA-approved ZANVASTRO (zilganersen, an antisense oligonucleotide) for Alexander disease, a first-in-class disease-modifying therapy for a rare progressive neurodegenerative disorder with no other approved therapies. The company acknowledged parallel setbacks in cardiovascular studies including the Novartis pelacarsen Phase 3 Lp(a)HORIZON miss reported September 4.
Sell-side analyst upgrades on Roivant Sciences (NASDAQ: ROIV) continued through Wednesday-Thursday September 9-10, 2026 following the Tuesday September 8 Pulmovant Phase 2 PHocus win in pulmonary hypertension associated with interstitial lung disease. TD Cowen raised its ROIV price target to $55 from $50 with a Buy rating; Jefferies raised to $52 from $42 with a Buy rating. These upgrades follow the Guggenheim ($46 from $42) and Piper Sandler ($55 from $40) targets published Wednesday September 9. Guggenheim estimated peak sales of approximately $3 billion in PH-ILD. Consensus analyst estimates now cluster around a $50-55 target range. The PHocus study achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001) with placebo-adjusted improvements of +35.2 meters six-minute walk distance and −53.2% NT-proBNP from baseline. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
MannKind Corporation (NASDAQ: MNKD) and Rose Pharma Inc. announced Wednesday September 9, 2026 a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational rapid-acting, short-duration glucagon-like peptide-1 (GLP-1) receptor agonist peptide formulated using MannKind's proprietary Technosphere dry-powder inhalation technology for chronic weight management. Under the deal, Rose Pharma receives an exclusive worldwide license to use MannKind's Technosphere platform for ROSE-010 development and commercialization; MannKind will provide pharmaceutical development services through completion of Phase 1b and receives an equity interest in Rose Pharma, royalties on future net sales, and a board seat. Rose Pharma retains responsibility for clinical development, regulatory strategy, and commercialization. The Technosphere platform delivers peptides to the deep lung via dry-powder inhaler and previously enabled Afrezza (inhaled insulin), positioning ROSE-010 as a differentiated non-injection GLP-1 option distinct from the once-daily injectable class dominated by semaglutide and tirzepatide, or the recently launched Wegovy pill and Foundayo (orforglipron) oral small-molecule options.
Amgen (NASDAQ: AMGN) presented Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, with Chief Medical Officer Paul Burton MD outlining a positioning for MariTide (maridebart cafraglutide, an antibody-peptide conjugate combining a GLP-1 receptor agonist peptide with a GIP receptor antagonist antibody scaffold) that could support 8-week or quarterly maintenance dosing (approximately 4-6 doses per year) after the induction phase. Phase 2 data showed about 20% weight loss at 52 weeks alongside lower triglycerides, lower high-sensitivity CRP, and an 11 mmHg drop in blood pressure. Two Phase 3 long-term extension studies (MARITIME-1 EXTENSION and MARITIME-2 EXTENSION) are examining lower maintenance dosing frequencies, plus a dedicated switch trial (MARITIME-SWITCH) testing conversion from weekly semaglutide or tirzepatide onto monthly MariTide. Six total Phase 3 MariTide trials enroll across obesity, obesity plus type 2 diabetes, obstructive sleep apnea, heart failure, and cardiovascular outcomes. Filing is planned late 2026 to early 2027 with anticipated launch 2027-2028. The 4% bone mineral density decline signal from Phase 1 remains a factor to watch in the Phase 3 dataset.
Altimmune Inc. (NASDAQ: ALT) presented Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, outlining a three-front development plan for pemvidutide (an investigational once-weekly GLP-1/glucagon dual agonist peptide with FDA Breakthrough Therapy Designation for MASH). PERFORMA is the Phase 3 MASH trial with a 5-year duration and 52-week accelerated-approval look; readout is expected in 2029. RECLAIM is the Phase 2 alcohol use disorder trial reporting consistent reductions in heavy drinking days, a 2.2-level drop in WHO Risk Drinking Level, improvement in zero-heavy-drinking-days, and lower phosphatidylethanol (PEth) alcohol-consumption biomarker levels versus placebo. RESTORE is the Phase 2 alcohol-related liver disease trial that has completed enrollment and uses FibroScan liver stiffness as the primary endpoint with 12-month readout and 6-month interim. Altimmune reported $519 million in cash as of June 30, 2026, funding the MASH Phase 3 program through the 2029 readout. Pemvidutide is one of three glucagon-containing peptide candidates in late-stage MASH development alongside Boehringer-Zealand's survodutide and Lilly's retatrutide.
Solstice Oncology, a Boston-based clinical-stage immuno-oncology company founded February 2026, announced Wednesday September 9, 2026 its formal launch and closing of an oversubscribed $225 million Series A financing to advance porustobart, a second-generation Fc-enhanced CTLA-4 monoclonal antibody licensed from Harbour BioMed. The Series A was led by RA Capital Management with participation from Canaan Partners, Forbion, and other investors. Porustobart is heading into a Phase 2 neoadjuvant trial combining with pembrolizumab (Merck's Keytruda) for microsatellite-stable clinical stage II-III colon cancer, targeting enrollment opening Q4 2026, plus a second undisclosed indication. Fc-enhancement is designed to improve the antibody's ability to deplete regulatory T-cells and enhance immunogenicity relative to first-generation CTLA-4 inhibitors like ipilimumab (Bristol Myers Squibb's Yervoy). The financing continues a Q3 2026 immuno-oncology financing wave and demonstrates continued investor appetite for differentiated checkpoint programs despite the maturity of the anti-PD-(L)1 class.
iBio Inc. (NYSE American: IBIO) announced at the Wells Fargo 21st Annual Healthcare Conference in Boston (Chief Executive Officer Martin Brenner DVM PhD in a Tuesday September 8, 2026 fireside chat) a broadening push into obesity and cardiometabolic disease anchored on long-acting antibody programs and a thesis that the market will shift toward combination treatment with durable maintenance. Lead program IBIO-610 is a long-acting Activin E antibody designed for infrequent dosing with strong target blockade, following a July 2026 disclosure that a single dose achieved near-complete active Activin E inhibition through 8 weeks in obese non-human primates. IBIO-600 (myostatin inhibitor) has completed single-ascending-dose enrollment and is headed toward Q1 2027 data readout. iBio also has an amylin program with four molecules differentiated by receptor selectivity profiles and a bispecific molecule for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The strategy is deliberately positioned as antibody-based rather than peptide-based to compete against MariTide, berobenatide, and the injectable-peptide GLP-1 class on dosing frequency and target-engagement duration.
Sell-side analysts moved fast Wednesday September 9, 2026 following Tuesday's positive Phase 2 PHocus readout from Roivant Sciences (NASDAQ: ROIV) subsidiary Pulmovant. Guggenheim raised its ROIV price target to $46 from $42 while maintaining a Buy rating, and Guggenheim estimated peak sales of approximately $3 billion in pulmonary hypertension associated with interstitial lung disease. Piper Sandler analyst Yasmeen Rahimi raised her price target to $55 from $40 with an Overweight rating. Roivant shares closed up approximately 17% Tuesday on the ERS Congress presentation of a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001), plus placebo-adjusted improvements of +35.2 meters six-minute walk distance and −357.7 pg/mL NT-proBNP (−53.2% from baseline). The Phase 3 PHrontier study in approximately 375 patients is enrolling. If PHrontier confirms the Phase 2 signal, mosliciguat would land in a PH-ILD market currently anchored by United Therapeutics' Tyvaso (treprostinil) — the only FDA-approved therapy specifically for PH-ILD — with orally-administered Merck Winrevair (sotatercept) as a pulmonary arterial hypertension option positioned differently.
Moonwalk Biosciences announced Tuesday September 8, 2026 an oversubscribed $70 million Series B financing to advance first-in-class adipose tissue-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. The round was co-led by Alpha Wave and YK Bioventures with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures, and Future Ventures. Proceeds will move lead candidate MW101 toward first-in-human clinical studies in late 2027 and support the broader adipose-targeted siRNA pipeline. Moonwalk's approach uses siRNA delivery specifically to adipose tissue to modulate non-incretin pathways governing energy homeostasis, adipogenesis, lipolysis, and thermogenesis while minimizing systemic effects. The company claims preclinical models show reductions in body weight and fat mass with lean-muscle preservation — the same value proposition Enveda's ENV-308 and Amgen's MariTide are pitching from different mechanisms. Lilly's investor participation extends the Lilly obesity-adjacent equity portfolio that already includes stakes in Superluminal Medicines (MC4R agonist, $60M Series B September 3), Verve Therapeutics (base editing, acquired 2025), and others.
Amgen (NASDAQ: AMGN) shares fell approximately 10% to $394.38 by midday Tuesday September 8, 2026 as investors continued to reprice the entire Lp(a)-lowering cardiovascular hypothesis following Novartis' Friday September 4 announcement that pelacarsen missed the primary MACE endpoint in the Phase 3 Lp(a)HORIZON trial. Amgen's olpasiran (RNAi Lp(a) suppressor) is the most direct readthrough: the Phase 3 OCEAN(a) trial is enrolling patients with elevated Lp(a) and established cardiovascular disease with a similar Lp(a)-lowering-plus-cardiovascular-outcome design and is estimated to read out 2027-2028. Lilly's lepodisiran (RNAi) is running in a broader group including primary-prevention patients, which analyst commentary suggests partly insulates it from the Novartis-specific readthrough. Silence Therapeutics' zerlasiran (RNAi) lowered Lp(a) by up to 85% at 36 weeks in ALPACAR-360; Silence has FDA feedback on a proposed Phase 3 design but is dependent on securing a development partner. The Lp(a) hypothesis question is now whether the drug class lowers hard cardiovascular outcomes, not whether the class lowers Lp(a) levels — that latter question was already answered in the affirmative.
Neurocrine Biosciences (NASDAQ: NBIX) hosted a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston Wednesday September 9, 2026 at 12:45 p.m. ET, disclosing that CRENESSITY (crinecerfont, a first-in-class oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist for classic congenital adrenal hyperplasia (CAH)) has reached approximately $750 million in quarterly run-rate revenue approximately 12 months after its FDA approval in December 2024 for pediatric patients aged 4 and older and adults with CAH. The company posted its first billion-dollar quarter in Q2 2026 and moved from a single-product company (Ingrezza for tardive dyskinesia) to three commercial products, with underlying Ingrezza volume growth of 17% and 2026 guidance at the $2.85 billion midpoint. CRF is a peptide hormone, and CRENESSITY blocks the CRF1 receptor to reduce excess ACTH secretion and androgen production in CAH — the mechanism replaces high-dose glucocorticoid therapy for many patients. Neurocrine reported zero debt and approximately $500 million in cash.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) shares closed at DKK 298.95 in Copenhagen on Monday September 7, 2026 (roughly 1.9% below Friday) after the company's simultaneous release of STEP Young Phase 3 pediatric semaglutide data (40.4% of children aged 6 to under 12 achieved BMI below the obesity threshold at week 68 versus 0% placebo) and confirmation that the HERMES and ATHENA Phase 3 ziltivekimab (anti-IL-6 monoclonal antibody) heart-failure trials had been terminated early after a data monitoring committee ruled the studies unlikely to succeed. Barclays' James Gordon cut the Novo Nordisk price target from DKK 310 to DKK 300 while maintaining an Equal Weight rating. Analyst commentary broadly framed the day as a scientific-engine-versus-diversification tension: the semaglutide franchise continues to add indication paths (pediatric obesity below 12 years is one of the last major label extensions available), while the non-GLP-1 diversification story tied to ziltivekimab now depends primarily on the post-acute heart-failure study that remains ongoing. Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington DC November 14-17.
Ascendis Pharma A/S (NASDAQ: ASND) announced Monday September 7, 2026 that the first sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, a sustained-release CNP peptide prodrug) in infants with achondroplasia aged 0 to under 2 years will be presented as a podium talk at the European Society for Paediatric Endocrinology (ESPE) 2026 congress in Marseille, France (September 8-10). The reACHin presentation (FC4.6) is scheduled for Tuesday September 8, 3:00-4:00 p.m. CEST by Genevieve Baujat MD. Additional presentations include the HighLiGHts Phase 3 trial design for lonapegsomatropin (TransCon hGH) across Turner syndrome, SHOX deficiency, small-for-gestational-age, and idiopathic short stature; hypoparathyroidism patient-reported-outcome data from adolescents; and a systematic literature review on pediatric growth hormone deficiency prevalence. Ascendis submitted the TransCon CNP marketing authorization application to the EMA in October 2025 with an EU decision expected Q4 2026. Navepegritide is engineered to provide continuous CNP receptor stimulation without the peak-and-trough kinetics that constrained earlier vosoritide (Voxzogo) dosing.
Roivant Sciences (NASDAQ: ROIV) and its Pulmovant subsidiary announced Sunday September 6, 2026 that Phase 2 PHocus topline results for mosliciguat (a once-daily inhaled soluble guanylate cyclase activator) in pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented Tuesday September 8, 2026 at 12:15 CEST (6:15 a.m. ET) at the European Respiratory Society Congress 2026 in Barcelona by Marc Humbert MD PhD (Université Paris-Saclay; French National Reference Center for Pulmonary Hypertension). The randomized double-blind placebo-controlled global trial enrolled 135 adults with PH-ILD; the primary endpoint is change from baseline in pulmonary vascular resistance at week 16, with the controlled period running through week 24. Roivant will host an investor call at 8:00 a.m. ET the same day. Mosliciguat is an sGC activator that works independently of heme and nitric oxide, differentiating it from sGC stimulators like riociguat. In the earlier Phase 1b ATMOS study a single inhaled dose produced a mean peak reduction in pulmonary vascular resistance of up to 38%. The PVR change versus placebo is the metric investors are watching; the same endpoint anchored the Phase 3 program for United Therapeutics' Tyvaso (treprostinil) in PH-ILD.
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion, 40% premium) continued through Sunday September 6, 2026 in the 10 SIX Swiss Exchange trading-day cooling-off period that began September 1 following Samsung Peptide AG's August 31 publication of the formal tender offer prospectus. Under Swiss takeover law, the main offer period commences Tuesday September 15, 2026 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction will consolidate one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.